|
FOXN3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.72219999769763E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.89900000002741E-06 |
| Normal-vs-Stage2 |
3.89400000022633E-08 |
| Normal-vs-Stage3 |
1.15580000004112E-06 |
| Normal-vs-Stage4 |
6.013400E-04 |
| Stage1-vs-Stage2 |
6.842000E-03 |
| Stage1-vs-Stage3 |
2.995600E-01 |
| Stage1-vs-Stage4 |
8.319000E-01 |
| Stage2-vs-Stage3 |
1.381360E-01 |
| Stage2-vs-Stage4 |
8.906400E-02 |
| Stage3-vs-Stage4 |
6.184800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.76259999995487E-06 |
| Normal-vs-AfricanAmerican |
3.278400E-02 |
| Normal-vs-Asian |
1.80798999999121E-05 |
| Caucasian-vs-AfricanAmerican |
5.713200E-01 |
| Caucasian-vs-Asian |
3.228200E-01 |
| AfricanAmerican-vs-Asian |
3.650200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.21779999995297E-06 |
| Normal-vs-Female |
1.34959999953388E-07 |
| Male-vs-Female |
6.671400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.046600E-04 |
| Normal-vs-Age(41-60Yrs) |
3.97980004507303E-09 |
| Normal-vs-Age(61-80Yrs) |
4.95070000550157E-08 |
| Normal-vs-Age(81-100Yrs) |
2.903800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.195500E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.843000E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.588000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.559600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.143800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.606000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.195000E-01 |
| Classical-VS-Follicular |
2.70228284193763E-12 |
| Classical-VS-Other |
3.967400E-01 |
| Classical-VS-Normal |
1.218730E-04 |
| Tall-VS-Follicular |
1.245390E-04 |
| Tall-VS-Other |
5.010400E-01 |
| Tall-VS-Normal |
2.625000E-03 |
| Follicular-VS-Other |
1.486590E-01 |
| Follicular-VS-Normal |
1.68790537102836E-11 |
| Other-VS-Normal |
2.567700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.60730000420273E-08 |
| Normal-vs-N1 |
1.842310E-04 |
| N0-vs-N1 |
3.049800E-01 |
|
|
